Takarinda Kudakwashe C, Sandy Charles, Masuka Nyasha, Hazangwe Patrick, Choto Regis C, Mutasa-Apollo Tsitsi, Nkomo Brilliant, Sibanda Edwin, Mugurungi Owen, Harries Anthony D, Siziba Nicholas
AIDS & TB Department, Ministry of Health & Child Care, Harare, Zimbabwe; International Union against Tuberculosis and Lung Disease, Paris, France.
AIDS & TB Department, Ministry of Health & Child Care, Harare, Zimbabwe.
Tuberc Res Treat. 2017;2017:6232071. doi: 10.1155/2017/6232071. Epub 2017 Mar 2.
. In 2013, the tuberculosis (TB) mortality rate was highest in southern Zimbabwe at 16%. We therefore sought to determine factors associated with mortality among registered TB patients in this region. . This was a retrospective record review of registered patients receiving anti-TB treatment in 2013. . Of 1,971 registered TB patients, 1,653 (84%) were new cases compared with 314 (16%) retreatment cases. There were 1,538 (78%) TB/human immunodeficiency virus (HIV) coinfected patients, of whom 1,399 (91%) were on antiretroviral therapy (ART) with median pre-ART CD4 count of 133 cells/uL (IQR, 46-282). Overall, 428 (22%) TB patients died. Factors associated with increased mortality included being ≥65 years old [adjusted relative risk (ARR) = 2.48 (95% CI 1.35-4.55)], a retreatment TB case [ARR = 1.34 (95% CI, 1.10-1.63)], and being HIV-positive [ARR = 1.87 (95% CI, 1.44-2.42)] whilst ART initiation was protective [ARR = 0.25 (95% CI, 0.22-0.29)]. Cumulative mortality rates were 10%, 14%, and 21% at one, two, and six months, respectively, after starting TB treatment. . There was high mortality especially in the first two months of anti-TB treatment, with risk factors being recurrent TB and being HIV-infected, despite a high uptake of ART.
2013年,津巴布韦南部的结核病死亡率最高,为16%。因此,我们试图确定该地区登记的结核病患者中与死亡率相关的因素。
这是一项对2013年接受抗结核治疗的登记患者的回顾性记录审查。
在1971名登记的结核病患者中,1653例(84%)为新发病例,314例(16%)为复治病例。有1538例(78%)结核病/人类免疫缺陷病毒(HIV)合并感染患者,其中1399例(91%)正在接受抗逆转录病毒治疗(ART),ART治疗前CD4细胞计数中位数为133个/微升(四分位间距,46 - 282)。总体而言,428例(22%)结核病患者死亡。与死亡率增加相关的因素包括年龄≥65岁[调整相对风险(ARR)= 2.48(95%置信区间1.35 - 4.55)]、复治结核病病例[ARR = 1.34(95%置信区间,1.10 - 1.63)]以及HIV阳性[ARR = 1.87(95%置信区间,1.44 - 2.42)],而开始ART治疗具有保护作用[ARR = 0.25(95%置信区间,0.22 - 0.29)]。开始抗结核治疗后1个月、2个月和6个月的累积死亡率分别为10%、14%和21%。
尤其是在抗结核治疗的头两个月死亡率很高,危险因素是复发性结核病和HIV感染,尽管ART治疗的接受率很高。